Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference
12 mai 2021 07h00 HE
|
Freeline Therapeutics
LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene...
Freeline Presents Data Highlighting Platform Technology at the American Society of Gene and Cell Therapy Annual Meeting 2021
11 mai 2021 07h00 HE
|
Freeline Therapeutics
LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program
08 févr. 2021 07h00 HE
|
Freeline Therapeutics
Targeting initiation of dose confirmation trial by end of 2021 with data readout by end of 2022 Initiation of Phase 3 pivotal trial targeted by mid-2023, with data readout and BLA filing targeted by...
Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
26 janv. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline to participate at Conferences during January 2021
04 janv. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
14 déc. 2020 07h00 HE
|
Freeline Therapeutics
Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with...
Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference
19 nov. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline appoints Mark Baldry as Chief Commercial Officer
02 nov. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit
30 oct. 2020 07h00 HE
|
Freeline Therapeutics
- Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes - Potentially increasing safety and efficacy in Freeline’s AAV delivery...
Freeline Reports Half Year 2020 Financial Results and Recent Business Highlights
29 oct. 2020 16h15 HE
|
Freeline Therapeutics
Will report updated durability data from Phase 1/2 B-AMAZE trial in Haemophilia B in Q4 Third wholly-owned programme expected to be in the clinic in 2021 Strong cash position with over $250 million...